EMERALD Trial | ORSERDU™ (elacestrant) Efficacy
Breast Cancer Ireland - There is a research study called EMERALD to determine whether an investigational oral endocrine treatment called elacestrant can help people with advanced or metastatic breast cancer. If you
EMERALD: Phase III trial of elacestrant (RAD1901) vs endocrine therapy for previously treated ER+ advanced breast cancer | Future Oncology
EMERALD Trial: Elacestrant for ER+/HER2- Metastatic Breast Cancer
Laila Agrawal, MD on X: "Results from #EMERALD with oral #SERD elacestrant presented at #SABCS21. Improved PFS from 2.79 to 1.91 mo with greater separation at 6mo and 12mo. I had the
Oncology Brothers on X: "3. #EMERALD trial for #Elacestrant HR+ mESR1 advanced breast CA -median PFS was 3.8 month - Common AE: musculoskeletal pain, nausea, increased cholesterol #bcsm https://t.co/xCWNyXRObk https://t.co/Jjwpif9xeq https://t.co ...
Overview of the EMERALD Trial of Elacestrant in ER+, HER2- Advanced Breast Cancer
EMERALD Trial | ORSERDU™ (elacestrant) Efficacy
Report Back from SABCS 2021: What's the Latest in MBC Research? — Our MBC Life
Elacestrant vs Endocrine Monotherapy in Advanced Breast Cancer: Phase III EMERALD Trial - The ASCO Post
Top Insights from the EMERALD Trial: Advanced Breast Cancer
Bertrand Delsuc on X: "$AZN Imfinzi plus bevacizumab met primary endpoint for progression-free survival in liver cancer eligible for embolisation in EMERALD-1 Phase III trial hit on PFS for durva+beva+TACE in HCC (
On trial: Emerald Insight Expert Briefings - Library Matters
EMERALD Study Orkin C. Lancet HIV. 2018 Jan;5(1):e23-e34.
ARV-trial.com Switch to D/C/F/TAF EMERALD Study ppt download
Paolo Tarantino on X: "EMERALD trial: significant, albeit modest PFS improvement with elacestrant vs AI/fulvestrant in ET-pretreated MBC patients Good tolerability for elacestrant, with main AE being nausea. Could become the first
ER+, HER2- Advanced Breast Cancer: Clinical Implications of the EMERALD Trial
EMERALD Phase 3 Trial of Elacestrant Versus Standard of Care Endocrine Therapy in Patients With ER+/HER2- Metastatic Breast Cancer: Updated Results by Duration of Prior CDK4/6i in Metastatic Setting
Resources to support your trial | Emerald Publishing
The EMERALD Trial Diabetic Substudy. EMERALD Diabetic Analysis To compare myocardial perfusion and infarct sizes in diabetic and non-diabetic patients. - ppt download
SABCS 2022: EMERALD phase 3 trial of elacestrant versus standard of care endocrine therapy in patients with ER+/HER2- metastatic breast cancer: Updated results by duration of prior CDK4/6i in metastatic setting
EMERALD Trial | ORSERDU™ (elacestrant) Efficacy
Resources to support your trial | Emerald Publishing
The EMERALD Trial: Elacestrant Mechanism of Action, Study Design, and Outcomes
Clinical outcomes of patients within the EMERALD trial of elacestrant... | Download Scientific Diagram
